Education
About Us
Working with TipRanks
Follow Us
Mahesh Krishnan Insider Profile
4 Followers
Mahesh Krishnan, Director at Chinook Therapeutics, holds 6.50K shares in Halozyme (Ticker: HALO), holds 0.00 shares in Chinook Therapeutics (Ticker: KDNY).
Mahesh Krishnan Chinook Therapeutics (KDNY)Director
Chinook Therapeutics (KDNY)
Director
Not Ranked
Mahesh Krishnan has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Mahesh Krishnan's holdings
Insider Roles
Director
Roles that Mahesh Krishnan holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Mahesh Krishnan
Mahesh Krishnan's Trading History
Chinook Therapeutics
Aug 11, 2023
―
Uninformative Sell
―
$0.00
Halozyme
Apr 29, 2024
Director
Uninformative Buy
―
$396.43K
List of latest transactions for each holding click on a transaction to see Mahesh Krishnan's performance on stock
You May Also Like
Mahesh Krishnan insider profile FAQ
What is the percentage of profitable transactions made by Mahesh Krishnan?
The percentage of profitable transactions made by Mahesh Krishnan is ―.
What is the average return per transaction made by Mahesh Krishnan?
The average return per transaction made by Mahesh Krishnan is ―.
What stocks does Mahesh Krishnan hold?
Mahesh Krishnan holds: KDNY, HALO stocks.
What was Mahesh Krishnan’s latest transaction?
Mahesh Krishnan latest transaction was an Uninformative Buy of ―.
What was Mahesh Krishnan's most profitable transaction?
Mahesh Krishnan’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Mahesh Krishnan's role in Chinook Therapeutics?
Mahesh Krishnan's role in Chinook Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.